Albany, NY -- (SBWIRE) -- 06/26/2019 -- Chronic Lower Back Pain Market Insights, Epidemiology and Market Forecast-2028
1. Chronic Lower Back Pain prevalence is estimated to range from approximately 17% to 43% in French healthcare workers and in the US adults, it was around 15%.
2. The general population Chronic Lower Back Pain prevalence was available for two countries, i.e., nearly 6% for Italy and 7-10% for the United Kingdom.
3. Chronic Lower Back Pain occurs more in women than men.
DelveInsight launched a new report on Chronic Lower Back Pain Market Insights, Epidemiology and Market Forecast-2028
Key benefits
1. Chronic Lower Back Pain market report covers a descriptive overview and comprehensive insight of the Chronic Lower Back Pain epidemiology and Chronic Lower Back Pain market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Chronic Lower Back Pain market report provides insights into current and emerging therapies.
3. Chronic Lower Back Pain market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Chronic Lower Back Pain market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Chronic Lower Back Pain market.
Request for sample pages
"Chronic Lower Back Pain prevalence in adults aged 20–69 years old was <15% in the United States."
Chronic Lower Back Pain is the second leading cause of disability among adults of the United States. There are many other methods that are used to manage pain from this condition. In general, Chronic Lower Back Pain therapeutic landscape is divided into conservative management and invasive treatments. The current conservative therapy includes the use of non-steroidal-anti-inflammatory drugs (NSAIDs), acetaminophen, muscle relaxants, or even a short course of opioid pain medication (Opioid analgesics (with or without paracetamol) may improve pain and function) in conjunction with non-pharmacological strategies, such as physical therapy, all of which lead to improvement in a majority of patients. Non-pharmacologic therapies are effective in certain clinical situations and can be added to the treatment program at any time. For maximum pain relief and reduced side effects, the active pharmaceutical ingredients have to be delivered to the specific site of inflammation and in a controlled manner, indicating a need for novel drug delivery mechanisms in pain management.
However, if conservative therapy fails to provide symptomatic relief, other CLBP treatments such as epidural steroid injections, facet injections, and radiofrequency ablations, are recommended. Unfortunately, even these more invasive procedures have not been shown to decrease the need for subsequent surgeries in patients with chronic pain secondary to herniated lumbar intervertebral discs.
To summarize, a better and clear understanding of the CLBP pathogenesis will significantly improve the Chronic Lower Back Pain treatment regimens and development of novel CLBP therapies. There is a need for further studies that may focus on revealing the precise mechanisms underlying Chronic Lower Back Pain pathogenesis, highlighting CLBP biomarkers and optimizing characteristics of drugs as well. With this, several companies have started working toward the development of new Chronic Lower Back Pain therapeutic options.
Chronic Lower Back Pain market is expected to experience a positive growth in the coming years owing to the already prescribed products along with the launch of distinctive CLBP emerging therapies in the coming years.
Chronic Lower Back Pain market dynamics is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world and expected the launch of emerging therapies during the forecast period of 2019-2028. Companies across the globe are thoroughly working toward the development of new Chronic Lower Back Pain treatment therapies.
The key players in Chronic Lower Back Pain market are:
1. Nektar Pharmaceuticals
2. Stayble Therapeutics
3. Pfizer
4. Teva
5. Braeburn Pharmaceuticals
6. Camurus AB
And many others
Drugs covered
1. NKTR-181
2. STA-363
3. Tanzumeb
4. Fasinumab
5. Buprenorphine
And many others
Table of contents
1. Report Introduction
2. Chronic Lower Back Pain Market Overview at a Glance
3. Chronic Lower Back Pain Disease Background and Overview
4. Chronic Lower Back Pain Epidemiology and Patient Population
5. CLBP Country-Specific Patient Population
5.1. United States
5.2. EU5
5.2.1. Germany
5.2.2. France
5.2.3. Italy
5.2.4. Spain
5.2.5. United Kingdom
5.3. Japan
6. Chronic Lower Back Pain Current Treatment and Medical Practices
7. CLBP Unmet Needs
8. Chronic Lower Back Pain Emerging Therapies
8.1. Key Cross Competition
8.2. NKTR-181: Nektar Pharmaceuticals
8.3. Fasinumab: Teva
8.4. Buprenorphine (CAM2038): Braeburn Pharmaceuticals/Camurus AB
9. Chronic Lower Back Pain Market Outlook
10. Country-Wise Market Analysis (2017-2028)
10.1. United States Market Size
10.2. Germany Market Size
10.3. France Market Size
10.4. Italy Market Size
10.5. Spain Market Size
10.6. United Kingdom Market Size
10.7. Japan
11. Market drivers
12. Market barriers
13. Appendix
14. Chronic Lower Back Pain Report Methodology
15. DelveInsight Capabilities
16. Disclaimer
17. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight